Biotech Bytes: Conversations with Biotechnology/Pharmaceutical IT Leaders
Biotech AI Strategy: Why Most Pharma AI Projects Fail & How to Fix It? ( ft.Rose LaRocca-Fisch)
Why It Matters
Biotech firms are racing to adopt AI, but without solid data and governance, they risk costly failures and regulatory pitfalls. Understanding the foundational steps Rose describes helps companies turn AI from a hype‑driven experiment into a reliable, compliant driver of faster drug development and operational efficiency.
Key Takeaways
- •AI amplifies existing data, process, and governance weaknesses.
- •Strong IT‑business alignment and OASIS framework enable scalable AI.
- •Secure, governed data infrastructure must precede AI deployments.
- •Clear business objectives prevent futile AI officer hires.
- •Biotech AI projects fail 75% due to data readiness gaps.
Pulse Analysis
During the Biotech Bytes episode, Rose LaRocca‑Fish explained why the majority of pharma and biotech AI initiatives stumble before reaching production. She cited industry surveys showing roughly 75 % of AI projects fail, largely because organizations rush to experiment without solid data, process, or control foundations. In her view, AI acts as a magnifying glass: it accelerates both strengths and weaknesses. Without clean, governed datasets and aligned business‑IT processes, even the most sophisticated large‑language models cannot deliver reliable insights for drug discovery, manufacturing, or clinical trial enrollment.
To address those gaps, LaRocca‑Fish introduced her OASIS framework—Operating Alignment for Scalable Impact and Sustainability. The model stresses four pillars: defining the work, aligning IT with business goals, assessing skills and capabilities, and building secure, cloud‑native infrastructure before layering AI. She highlighted recent shifts toward enterprise‑grade AI platforms that incorporate identity‑access management, SD‑WAN, and rigorous output governance, especially critical in regulated environments where FDA and EU guidance demand data integrity and Part 11 compliance. A CIO who enforces this foundation turns IT from a cost center into a proactive value partner.
Practical takeaways for biotech leaders include establishing a clear AI business case before appointing a chief AI officer, and focusing early pilots on high‑impact areas such as manufacturing yield optimization or patient‑enrollment acceleration. LaRocca‑Fish advises quarterly roadmap reviews to keep pace with the exponential evolution of tools like ChatGPT, Copilot, and Databricks. By securing data pipelines, enforcing governance, and continuously aligning technology with measurable outcomes, companies can convert AI from a hype‑driven experiment into a sustainable engine for revenue growth and operational efficiency.
Episode Description
AI is moving incredibly fast across the life sciences sector, but many organizations still struggle to build systems that deliver real operational value. In this episode, tech leader Rose LaRocca-Fisch explains why strong data governance and business alignment must come before chasing software trends. Please visit our website to get more information: https://swangroup.net/
Rose shares her practical leadership experience guiding pharmaceutical companies, CDMOs, and global biotech organizations through massive growth. The discussion breaks down why high-profile tech implementations collapse and outlines the exact steps needed to prepare your infrastructure for enterprise-grade tools.
Key themes covered in this conversation:
Why does advanced software amplify existing operational flaws instead of fixing them
The OASIS framework for sustainable and scalable IT transformation
How data readiness directly impacts clinical trial success and manufacturing yields
Real-world applications using platforms like Databricks to speed up patient enrollment
The shift toward AI-assisted work and managing data integrity risks
Links from this episode:
Get to know more about Steven Swan: https://www.linkedin.com/in/swangroup
Get to know more about Rose LaRocca-Fisch: https://www.linkedin.com/in/rose-larocca-fisch
🔔𝐃𝐨𝐧'𝐭 𝐟𝐨𝐫𝐠𝐞𝐭 𝐭𝐨 𝐬𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞 𝐭𝐨 𝐨𝐮𝐫 𝐜𝐡𝐚𝐧𝐧𝐞𝐥 𝐟𝐨𝐫 𝐦𝐨𝐫𝐞 𝐮𝐩𝐝𝐚𝐭𝐞𝐬.
https://www.youtube.com/@Biotech_Bytes/?sub_confirmation=1
🔗 Stay Connected With Us.
LinkedIn: https://www.linkedin.com/company/the-swan-group/
Website: https://swangroup.net/
=============================
🎬Suggested videos for you:
▶️ https://www.youtube.com/watch?v=CaHwarSYhrA
▶️ https://www.youtube.com/watch?v=be8szNVFrNk
▶️ https://www.youtube.com/watch?v=_Be6WEEy2JM
▶️ https://www.youtube.com/watch?v=mqpB3pGywkU
▶️ https://www.youtube.com/watch?v=w9QyuG6p3Ys
=============================
#biotechai #pharmatech #lifesciences #datagovernance #clinicaltrials #ittransformation
Comments
Want to join the conversation?
Loading comments...